Efficacy of the albumin-to-fibrinogen ratio as a predictive marker of advanced-stage cervical cancer
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20243584Keywords:
Albumin to fibrinogen ratio, Cervical cancer, Efficacy, Predictive markerAbstract
Background: Cervical cancer is the fourth most prevalent cause of mortality from cancer in women worldwide. Inflammation is a significant predictor of cancer. Indications of inflammation include a high fibrinogen level and a low albumin level. Increased fibrinogen levels have been connected to the development and spread of cancer as well as a pro-inflammatory condition. The albumin/fibrinogen ratio (AFR), which is a combination of albumin and fibrinogen, has been proposed as a novel marker of inflammation. Therefore, this study aimed to evaluate the efficacy of the albumin-to-fibrinogen ratio as a predictive marker of advanced-stage cervical cancer.
Methods: This was a prospective observational study conducted in the department of gynecological oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh during the period from July 2022 to June 2023. In our study, we included 70 women with biopsy-proven cervical cancer attending the inpatient and outpatient departments of the gynecological oncology department at BSMMU.
Results: The mean age of the patients was 45.37±9.54 years. The mean albumin to fibrinogen ratio was lower in the advanced-stage group (9.77±1.21) compared to that in the early-stage group (10.74±1.54) and the difference between the two groups was statistically highly significant (p=0.005). Considering 10.7 as the cut-off value (by ROC curve) we found the sensitivity, specificity, PPV, and NPV for AFR<10.7 was 85.71%, 62.86%, 69.77%, and 81.48%, respectively.
Conclusions: Our study findings show that the albumin-to-fibrinogen ratio (AFR) emerges as a promising prognostic marker to differentiate between advanced and early-stage cases and could aid in clinical decision-making.
Metrics
References
Pimple S, Mishra G. Cancer cervix: epidemiology and disease burden. Cytojournal. 2022;19:21.
Prabhu M, Eckert LO. Development of World Health Organization (WHO) recommendations for appropriate clinical trial endpoints for next-generation human papillomavirus (HPV) vaccines. Papillomavirus Res. 2016;2:185-9.
Hoque MR, Haque E, Karim MR. Cervical cancer in low‐income countries: A Bangladeshi perspective. Int J Gynecol Obstet. 2021;152(1):19-25.
Nessa A, Chowdhury SB, Fatima P, Kamal M, Sharif M, Azad AK. Cervical cancer screening program in Bangladesh. Bangladesh J Obstet Gynecol. 2020;33(1):63-73.
Zhang Y, Xiao G. Prognostic significance of the ratio of fibrinogen and albumin in human malignancies: a meta-analysis. Cancer Manag Res. 2019;11:3381-93.
Belinskaia DA, Voronina PA, Shmurak VI, Jenkins RO, Goncharov NV. Serum albumin in health and disease: esterase, antioxidant, transporting and signaling properties. Int J Mol Sci. 2021;22(19):10318.
Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9(1):1-16.
Kattula S, Byrnes JR, Wolberg AS. Fibrinogen and Fibrin in Hemostasis and Thrombosis. Arterioscler Thromb Vasc Biol. 2017;37(3)
Dai T, Peng L, Lin G, Li Y, Yao J, Deng Y, et al. Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma. J Gastrointest Oncol. 2019;10(6):1049-63.
Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1-7.
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143:22-36.
Giuliano AR, Joura EA, Garland SM, Huh WK, Iversen OE, Kjaer SK, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol. 2019;154(1):110-7.
Malhone C, Longatto-Filho A. Cervical, ovarian and endometrial tumor markers: potential clinical value. Semin Ultrasound CT MRI. 2019;40:350-7.
Rijkaart DC, Berkhof J, Van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screening. Int J Cancer. 2012;130(3):602-10.
Saleh M, Virarkar M, Javadi S, Elsherif SB, De Castro Faria S, Bhosale P. Cervical cancer: 2018 revised international federation of gynecology and obstetrics staging system and the role of imaging. AJR Am J Roentgenol. 2020;214(5):1182-95.
Li B, Deng H, Lei B, Chen L, Zhang X, Sha D. The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: a meta-analysis. Front Oncol. 2022;12:985377.
Li F, He H. Assessing the accuracy of diagnostic tests. Shanghai Arch Psychiatr. 2018;30(3):207-12.
Khanam A, Jesmin ZF, Begum F, Akhter N, Akter M, Nahar S, et al. Prevalence of cervical intraepithelial neoplasia (CIN) at Khulna Division of Bangladesh. Bangladesh J Obstet Gynaecol. 2018;33(1):21-8.
Aminimoghaddam S, Mahmoudzadeh F, Maghsoudnia A. Cervical cancer along with unknown cirrhosis: a misdiagnosed case. J Reprod Infertil. 2015;16(3):174-7.
Huang L, Mo Z, Zhang L, Qin S, Li S. Diagnostic value of albumin to fibrinogen ratio in cervical cancer. Int J Biol Markers. 2020;35(2):66-73.
Sun DW, An L, Lv GY. Albumin-fibrinogen ratio and fibrinogen-prealbumin ratio as promising prognostic markers for cancers: an updated meta-analysis. World J Surg Oncol. 2020;18:1-15.
An Q, Liu W, Yang Y, Yang B. Preoperative fibrinogen-to-albumin ratio, a potential prognostic factor for patients with stage IB-IIA cervical cancer. BMC Cancer. 2020;20:1-8.
